Claims for Patent: 12,398,087

Summary for Patent: 12,398,087

Title:	Methods of making bempedoic acid and compositions of the same
Abstract:	The invention provides methods of preparing 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid and methods of making a pharmaceutical material comprising a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid. Also provided are compositions and pharmaceutical materials including a purified amount of 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid as well as methods of treating various diseases and conditions using the compositions and pharmaceutical materials.
Inventor(s):	Richard Copp, Mohamed Abdelnasser, Christopher M. Cimarusti, Jonathan Lane, Michael Barkman, Rasidul Amin, Arthur John Cooper, Damodaragounder Gopal, Philipp Selig
Assignee:	Olon Ricerca Bioscience LLC , Esperion Therapeutics Inc
Application Number:	US18/657,105
Patent Claims:	1. A pharmaceutical material comprising a compound of formula (V): wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 98% by weight based on the total weight of the pharmaceutical material and the pharmaceutical material comprises 0.001% to 0.15% of a compound of formula (VI): or a pharmaceutically acceptable salt thereof, based on the total weight of the pharmaceutical material. 2. The pharmaceutical material of claim 1, wherein the compound of formula (V) is a crystalline form of the compound of formula (V), which exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.4±0.2, 17.9±0.2, 18.8±0.2, 19.5±0.2, and 20.7±0.2. 3. The pharmaceutical material of claim 2, wherein the crystalline form of the compound of formula (V) is characterized by an X-ray powder diffraction pattern substantially the same as shown in FIG. 4 . 4. The pharmaceutical material of claim 2, wherein the crystalline form of the compound of formula (V) has a melting point onset as determined by differential scanning calorimetry in the range of from 90° C. to 94° C. 5. The pharmaceutical material of claim 2, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.5% by weight based on the total weight of the pharmaceutical material. 6. The pharmaceutical material of claim 2, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.7% by weight based on the total weight of the pharmaceutical material. 7. The pharmaceutical material claim 2, wherein the pharmaceutical material comprises the compound of formula (V) in an amount greater than 99.9% by weight based on the total weight of the pharmaceutical material. 8. A pharmaceutical material comprising the compound of formula (V): in an amount of from about 98% to about 102% by weight based on the total weight of the pharmaceutical material, as determined by a high performance liquid chromatography (HPLC) assay, and less than or equal to 0.15% of a compound of formula (VI): or a pharmaceutically acceptable salt thereof, based on the total weight of the pharmaceutical material, wherein the total batch weight of the pharmaceutical material is at least 100 kg. 9. The pharmaceutical material of claim 8, wherein the HPLC assay uses a C18 column (4.6 mm i.d.×150 mm, 2.5 μm) at a temperature of about 40° C., with isocratic elution of a mobile phase comprising about 0.05% phosphoric acid in water/acetonitrile (about 50:50) at a flow rate of about 1.2 mL/minute, and detection at 215 nm, wherein the retention time of the compound of formula (V) is about 4.6 minutes. 10. The pharmaceutical material of claim 1, further comprising 0.001% to 0.15% of a compound of formula (VIII): or a pharmaceutically acceptable salt thereof, based on the total weight of the pharmaceutical material. 11. A pharmaceutical formulation comprising: a pharmaceutical material comprising: the compound of formula (V): and a compound of formula (VI): or a pharmaceutically acceptable salt thereof, wherein the compound of formula (VI) is present in an amount between 0.001% to 0.15% based on the total weight of the pharmaceutical material; and a pharmaceutically acceptable excipient, wherein the pharmaceutical formulation is prepared using a crystalline form of the compound of formula (V). 12. The pharmaceutical formulation of claim 11, wherein the compound of formula (V) is present in a therapeutically effective amount. 13. The pharmaceutical formulation of claim 11, wherein the compound of formula (V) is present in the pharmaceutical material in an amount greater than 98% by weight based on the total weight of the pharmaceutical material. 14. The pharmaceutical formulation of claim 11, wherein the compound of formula (V) is present in the pharmaceutical material in an amount greater than 99% by weight based on the total weight of the pharmaceutical material. 15. The pharmaceutical formulation of claim 11, wherein the crystalline form of the compound of formula (V) exhibits an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ): 10.4±0.2, 17.9±0.2, 18.8±0.2, 19.5±0.2, and 20.7±0.2. 16. The pharmaceutical formulation of claim 11, wherein the pharmaceutical formulation is formulated for administration as an oral dosage form. 17. The pharmaceutical formulation of claim 16, wherein the oral dosage form is a tablet.